Perimeter B-Series OCT with ImgAssist AI 2.0 Demonstrates Super-Superiority Compared to Standard-of-Care in Pivotal Clinical Trial
Portfolio Pulse from
Perimeter Medical Imaging AI's B-Series OCT with ImgAssist AI 2.0 has shown superior results in a clinical trial for breast-conserving surgeries, meeting primary endpoints with significant reduction in residual cancer. The company plans to submit an FDA PMA application in early 2025.
November 20, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Perimeter Medical Imaging AI's B-Series OCT with ImgAssist AI 2.0 demonstrated superior results in a clinical trial, potentially boosting its market position. An FDA PMA application is expected in early 2025.
The positive clinical trial results for Perimeter's B-Series OCT system with ImgAssist AI 2.0 indicate a significant advancement over current methods, which could enhance the company's competitive edge in the medical imaging market. The upcoming FDA PMA application further supports potential market expansion and investor interest.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100